AstraZeneca Common Stock vs Non Current Liabilities Total Analysis

AZN Stock

USD 76.90 0.14 0.18%

AstraZeneca PLC financial indicator trend analysis is way more than just evaluating AstraZeneca PLC ADR prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether AstraZeneca PLC ADR is a good investment. Please check the relationship between AstraZeneca PLC Common Stock and its Non Current Liabilities Total accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

Common Stock vs Non Current Liabilities Total

Common Stock vs Non Current Liabilities Total Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of AstraZeneca PLC ADR Common Stock account and Non Current Liabilities Total. At this time, the significance of the direction appears to have strong relationship.

The correlation between AstraZeneca PLC's Common Stock and Non Current Liabilities Total is 0.65. Overlapping area represents the amount of variation of Common Stock that can explain the historical movement of Non Current Liabilities Total in the same time period over historical financial statements of AstraZeneca PLC ADR, assuming nothing else is changed. The correlation between historical values of AstraZeneca PLC's Common Stock and Non Current Liabilities Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock of AstraZeneca PLC ADR are associated (or correlated) with its Non Current Liabilities Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Current Liabilities Total has no effect on the direction of Common Stock i.e., AstraZeneca PLC's Common Stock and Non Current Liabilities Total go up and down completely randomly.

Correlation Coefficient

0.65

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Common Stock

Non Current Liabilities Total

Most indicators from AstraZeneca PLC's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into AstraZeneca PLC ADR current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

At this time, AstraZeneca PLC's Tax Provision is very stable compared to the past year. As of the 20th of May 2024, Enterprise Value is likely to grow to about 218.7 B, while Selling General Administrative is likely to drop about 11.8 B.

	2021	2022	2023	2024 (projected)
Interest Expense	1.3B	1.3B	1.6B	1.7B
Depreciation And Amortization	6.5B	5.6B	4.9B	5.2B

Interest Expense Depreciation And Amortization

AstraZeneca PLC fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Total Liab	Total Current Assets	Short Term Debt	Other Stockholder Equity	Capital Stock	Common Stock	Other Assets	Intangible Assets	Other Liab
Total Assets		0.94	0.34	0.95	0.9	0.83	0.85	-0.38	0.3	0.33	0.99	-0.07	0.18	0.91	-0.36	0.85	0.84	0.96	0.69	0.79	0.93	0.74	0.74	0.91	0.96	0.43
Short Long Term Debt Total	0.94		0.17	0.88	0.77	0.84	0.97	-0.64	0.31	0.09	0.97	-0.31	-0.08	0.78	-0.49	0.9	0.89	0.96	0.53	0.77	0.86	0.72	0.72	0.96	0.95	0.48
Other Current Liab	0.34	0.17		0.47	0.4	0.02	0.12	0.22	-0.58	0.12	0.31	0.31	0.19	0.38	0.07	0.05	-0.01	0.25	0.14	0.45	0.39	-0.08	-0.08	0.14	0.27	-0.02
Total Current Liabilities	0.95	0.88	0.47		0.87	0.77	0.78	-0.36	0.13	0.34	0.93	-0.03	0.22	0.91	-0.31	0.72	0.71	0.9	0.64	0.9	0.88	0.64	0.64	0.87	0.88	0.3
Total Stockholder Equity	0.9	0.77	0.4	0.87		0.63	0.65	-0.2	0.11	0.41	0.85	0.01	0.31	0.84	-0.22	0.55	0.75	0.74	0.76	0.75	0.97	0.69	0.69	0.7	0.82	0.08
Property Plant And Equipment Net	0.83	0.84	0.02	0.77	0.63		0.76	-0.39	0.54	0.37	0.83	-0.09	0.2	0.84	-0.26	0.85	0.75	0.88	0.75	0.58	0.66	0.88	0.88	0.88	0.8	0.57
Net Debt	0.85	0.97	0.12	0.78	0.65	0.76		-0.78	0.23	-0.15	0.9	-0.44	-0.31	0.64	-0.53	0.86	0.86	0.89	0.34	0.73	0.79	0.65	0.65	0.91	0.9	0.48
Retained Earnings	-0.38	-0.64	0.22	-0.36	-0.2	-0.39	-0.78		-0.03	0.57	-0.47	0.75	0.71	-0.1	0.6	-0.49	-0.6	-0.47	0.13	-0.47	-0.37	-0.35	-0.35	-0.58	-0.49	-0.23
Accounts Payable	0.3	0.31	-0.58	0.13	0.11	0.54	0.23	-0.03		0.42	0.3	0.08	0.29	0.36	-0.06	0.54	0.31	0.4	0.44	-0.05	0.12	0.51	0.51	0.33	0.32	0.53
Cash	0.33	0.09	0.12	0.34	0.41	0.37	-0.15	0.57	0.42		0.22	0.5	0.92	0.56	0.18	0.15	0.08	0.25	0.77	0.1	0.22	0.35	0.35	0.15	0.16	0.04
Non Current Assets Total	0.99	0.97	0.31	0.93	0.85	0.83	0.9	-0.47	0.3	0.22		-0.15	0.05	0.86	-0.44	0.89	0.84	0.97	0.6	0.79	0.91	0.72	0.72	0.91	0.99	0.51
Non Currrent Assets Other	-0.07	-0.31	0.31	-0.03	0.01	-0.09	-0.44	0.75	0.08	0.5	-0.15		0.76	0.23	0.82	-0.18	-0.36	-0.13	0.3	-0.1	-0.11	-0.11	-0.11	-0.22	-0.19	-0.02
Cash And Short Term Investments	0.18	-0.08	0.19	0.22	0.31	0.2	-0.31	0.71	0.29	0.92	0.05	0.76		0.48	0.54	-0.03	-0.09	0.08	0.69	0.02	0.11	0.18	0.18	0.01	-0.02	-0.11
Common Stock Shares Outstanding	0.91	0.78	0.38	0.91	0.84	0.84	0.64	-0.1	0.36	0.56	0.86	0.23	0.48		-0.06	0.71	0.6	0.86	0.82	0.76	0.81	0.75	0.75	0.77	0.82	0.38
Short Term Investments	-0.36	-0.49	0.07	-0.31	-0.22	-0.26	-0.53	0.6	-0.06	0.18	-0.44	0.82	0.54	-0.06		-0.44	-0.45	-0.42	0.1	-0.28	-0.32	-0.22	-0.22	-0.39	-0.47	-0.3
Non Current Liabilities Total	0.85	0.9	0.05	0.72	0.55	0.85	0.86	-0.49	0.54	0.15	0.89	-0.18	-0.03	0.71	-0.44		0.8	0.95	0.46	0.52	0.66	0.65	0.65	0.88	0.9	0.79
Inventory	0.84	0.89	-0.01	0.71	0.75	0.75	0.86	-0.6	0.31	0.08	0.84	-0.36	-0.09	0.6	-0.45	0.8		0.82	0.56	0.52	0.8	0.71	0.71	0.88	0.83	0.35
Total Liab	0.96	0.96	0.25	0.9	0.74	0.88	0.89	-0.47	0.4	0.25	0.97	-0.13	0.08	0.86	-0.42	0.95	0.82		0.58	0.73	0.81	0.69	0.69	0.95	0.96	0.62
Total Current Assets	0.69	0.53	0.14	0.64	0.76	0.75	0.34	0.13	0.44	0.77	0.6	0.3	0.69	0.82	0.1	0.46	0.56	0.58		0.42	0.65	0.81	0.81	0.56	0.55	0.15
Short Term Debt	0.79	0.77	0.45	0.9	0.75	0.58	0.73	-0.47	-0.05	0.1	0.79	-0.1	0.02	0.76	-0.28	0.52	0.52	0.73	0.42		0.81	0.53	0.53	0.71	0.76	0.13
Other Stockholder Equity	0.93	0.86	0.39	0.88	0.97	0.66	0.79	-0.37	0.12	0.22	0.91	-0.11	0.11	0.81	-0.32	0.66	0.8	0.81	0.65	0.81		0.71	0.71	0.76	0.9	0.19
Capital Stock	0.74	0.72	-0.08	0.64	0.69	0.88	0.65	-0.35	0.51	0.35	0.72	-0.11	0.18	0.75	-0.22	0.65	0.71	0.69	0.81	0.53	0.71		1.0	0.68	0.72	0.38
Common Stock	0.74	0.72	-0.08	0.64	0.69	0.88	0.65	-0.35	0.51	0.35	0.72	-0.11	0.18	0.75	-0.22	0.65	0.71	0.69	0.81	0.53	0.71	1.0		0.68	0.72	0.38
Other Assets	0.91	0.96	0.14	0.87	0.7	0.88	0.91	-0.58	0.33	0.15	0.91	-0.22	0.01	0.77	-0.39	0.88	0.88	0.95	0.56	0.71	0.76	0.68	0.68		0.88	0.47
Intangible Assets	0.96	0.95	0.27	0.88	0.82	0.8	0.9	-0.49	0.32	0.16	0.99	-0.19	-0.02	0.82	-0.47	0.9	0.83	0.96	0.55	0.76	0.9	0.72	0.72	0.88		0.56
Other Liab	0.43	0.48	-0.02	0.3	0.08	0.57	0.48	-0.23	0.53	0.04	0.51	-0.02	-0.11	0.38	-0.3	0.79	0.35	0.62	0.15	0.13	0.19	0.38	0.38	0.47	0.56

Click cells to compare fundamentals

AstraZeneca PLC Account Relationship Matchups

AstraZeneca PLC fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	61.4B	66.7B	105.4B	96.5B	101.1B	106.2B
Short Long Term Debt Total	18.2B	20.4B	30.8B	29.2B	28.6B	30.1B
Other Current Liab	2.1B	508M	748M	1.5B	21.7B	22.8B
Total Current Liabilities	18.1B	20.3B	22.6B	26.3B	30.5B	32.1B
Total Stockholder Equity	13.1B	15.6B	39.3B	37.0B	39.1B	41.1B
Property Plant And Equipment Net	8.3B	8.9B	10.2B	9.4B	10.5B	6.8B
Net Debt	12.9B	12.5B	24.5B	23.1B	22.8B	23.9B
Retained Earnings	2.8B	5.3B	1.7B	(574M)	1.5B	1.4B
Accounts Payable	14.0B	15.8B	18.9B	19.0B	3.3B	3.1B
Cash	5.4B	7.8B	6.3B	6.2B	5.8B	4.7B
Non Current Assets Total	45.8B	47.2B	79.1B	73.9B	76.1B	79.9B
Non Currrent Assets Other	1.5B	1.7B	1.1B	1.1B	1.1B	1.4B
Cash And Short Term Investments	6.2B	8.0B	6.4B	6.4B	5.9B	5.8B
Common Stock Shares Outstanding	2.6B	2.6B	2.9B	3.1B	3.1B	2.9B
Liabilities And Stockholders Equity	61.4B	66.7B	105.4B	96.5B	101.1B	106.2B
Non Current Liabilities Total	28.7B	30.8B	43.5B	33.1B	31.4B	33.0B
Inventory	3.2B	4.0B	9.0B	4.7B	5.4B	5.7B
Total Liab	46.8B	51.1B	66.1B	59.4B	62.0B	65.1B
Total Current Assets	15.6B	19.5B	26.2B	22.6B	25.1B	15.3B
Short Term Debt	2.0B	2.4B	1.9B	5.5B	5.4B	5.7B
Other Stockholder Equity	8.4B	8.4B	35.6B	35.6B	35.6B	37.4B
Other Assets	3.5B	4.3B	5.3B	4.2B	4.8B	5.0B
Intangible Assets	20.8B	20.9B	42.4B	39.3B	38.1B	40.0B
Other Liab	10.3B	10.5B	13.0B	8.5B	9.8B	6.7B
Long Term Debt	15.7B	17.5B	28.1B	23.0B	22.4B	11.3B
Good Will	11.7B	11.8B	20.0B	19.8B	20.0B	21.1B
Other Current Assets	971M	1.9B	105M	11.5B	116M	110.2M
Property Plant Equipment	8.3B	8.9B	10.2B	9.4B	10.9B	7.9B
Current Deferred Revenue	28M	1.6B	1.0B	181M	149M	156.5M
Net Receivables	5.2B	5.7B	10.8B	9.9B	13.6B	14.2B
Property Plant And Equipment Gross	8.3B	8.9B	10.2B	9.4B	19.1B	20.1B
Accumulated Other Comprehensive Income	1.6B	1.6B	1.6B	1.6B	1.6B	1.7B
Noncontrolling Interest In Consolidated Entity	1.6B	1.5B	16M	21M	23M	21.9M
Additional Paid In Capital	8.1B	8.1B	35.3B	35.3B	35.3B	37.1B
Net Tangible Assets	(19.4B)	(17.2B)	(23.1B)	(22.1B)	(19.9B)	(20.9B)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether AstraZeneca PLC ADR offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AstraZeneca PLC's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Astrazeneca Plc Adr Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Astrazeneca Plc Adr Stock:

How To Invest In AstraZeneca

Details

Is AstraZeneca Stock a good investment?

Details

What is AstraZeneca PLC's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

Note that the AstraZeneca PLC ADR information on this page should be used as a complementary analysis to other AstraZeneca PLC's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.

Complementary Tools for AstraZeneca Stock analysis

When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.

	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
	Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
	Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum
	Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings
	Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
	Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators
	AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities
	Content Syndication Quickly integrate customizable finance content to your own investment portal
	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital
	Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges
	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules

Is AstraZeneca PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AstraZeneca PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.207

Dividend Share

2.9

Earnings Share

2.02

Revenue Per Share

2.5512

Quarterly Revenue Growth

0.165

The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between AstraZeneca PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if AstraZeneca PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AstraZeneca PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

AstraZeneca Common Stock vs Non Current Liabilities Total Analysis

Common Stock vs Non Current Liabilities Total

Common Stock vs Non Current Liabilities Total Correlation Analysis

Correlation Coefficient

Common Stock

Non Current Liabilities Total

AstraZeneca PLC fundamental ratios Correlations

AstraZeneca PLC Account Relationship Matchups

High Positive Relationship

High Negative Relationship

AstraZeneca PLC fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for AstraZeneca Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 1.0	Capital Stock
Non Current Assets Total	+ 0.99	Total Assets
Intangible Assets	+ 0.99	Non Current Assets Total
Net Debt	+ 0.97	Short Long Term Debt Total
Non Current Assets Total	+ 0.97	Short Long Term Debt Total
Other Stockholder Equity	+ 0.97	Total Stockholder Equity

Retained Earnings	- 0.78	Net Debt
Retained Earnings	- 0.64	Short Long Term Debt Total
Inventory	- 0.6	Retained Earnings
Other Assets	- 0.58	Retained Earnings
Accounts Payable	- 0.58	Other Current Liab
Short Term Investments	- 0.53	Net Debt